Keyword: Pfizer

Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.

With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.

Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks.

Sangamo saw its stock on the up this morning after it posted updates to a series of its trials using a new form of gene editing and cell therapies.

Artios Pharma is the latest biotech to call a pharma executive into the startup fold as it poaches Ian Smith, M.D., as its new chief medical officer.

SpringWorks Therapeutics raised $125 million to advance its two lead candidates, both of which are in development for noncancerous tumors.

Sickle cell disease biotech Imara has nabbed Pfizer’s clinical rare disease lead Willem H. Scheele, M.D., as its new chief medical officer.

Nimbus promoted Jennifer Rocnik, Ph.D., to vice president of biology and Alan Collis, Ph.D., will serve as vice president of preclinical development.

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis

Vivet is in the crosshairs of Big Pharma Pfizer as the U.S. giant looks to get in on the new industry craze of buying up small gene therapy biotechs.